Pure Global AI
NCT06405139Recruiting

Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine as Conversion Therapy of Locally Advanced Colorectal Cancer

Phase II Study of Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine as Conversion Therapy for Patients With Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Colorectal Cancer
Drug/Device/Intervention
Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location
Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
May 06, 2024
End date
Apr 30, 2027
Enrollment
36 participants
Primary outcome

Organ-sparing R0 Resection Rate

Summary

Neoadjuvant chemotherapy has gained acceptance in treating locally advanced breast cancer,
 esophageal cancer, gastric cancer, and rectal cancer. However, the role of neoadjuvant
 chemotherapy for locally advanced colon cancer is still in the exploratory stage. The
 objective of this study is to explore the efficacy and safety of nanoliposomal irinotecan and
 oxaliplatin combined with capecitabine as a novel conversion therapy for locally advanced
 colorectal cancer patients.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06405139
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06405139 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.